Table 3.
Cumulative incidence rates of posttransplant lymphoproliferative disorder adjusted per 100 person‐years of treatment exposure by donor kidney subtype and time of onset
| n (incidence rate) | |||
|---|---|---|---|
| Belatacept MI | Belatacept LI | CsA | |
| UNOS ECD | |||
| Months 0–12 | 1 (0.82) | 2 (1.74) | 0 |
| Months 12–24 | 1 (0.87) | 1 (0.91) | 0 |
| Months 24–48 | 0 | 0 | 0 |
| Months 48–60 | 0 | 0 | 1 (2.05) |
| Months 60–84 | 0 | 0 | 0 |
| Overall | 2 (0.34) | 3 (0.50) | 1 (0.19) |
| DCD | |||
| Overall | 0 | 0 | 0 |
| Anticipated CIT ≥24 h | |||
| Months 0–36 | 0 | 0 | 0 |
| Months 36–48 | 0 | 1 (3.89) | 0 |
| Months 48–60 | 0 | 2 (9.59) | 0 |
| Months 60–84 | 0 | 0 | 0 |
| Overall | 0 | 3 (1.60) | 0 |
CIT, cold ischemia time; CsA, cyclosporine; DCD, donation after cardiac death; ECD, expanded criteria donor; LI, less intensive; MI, more intensive; UNOS, United Network for Organ Sharing.